Arrowstreet Capital’s Enzo Biochem, Inc. ENZ Stock Holding History

Arrowstreet Capital’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-287,375	Closed	-$2.34M	–	1378
2017 Q4	$2.34M	Sell	287,375 -101,938	-26%	-$974K	0.01%	780
2017 Q3	$4.08M	Buy	389,313 +44,263	+13%	+$491K	0.01%	533
2017 Q2	$3.81M	Sell	345,050 -37,900	-10%	-$353K	0.01%	521
2017 Q1	$3.21M	Buy	+382,950	New	+$2.7M	0.01%	683
2016 Q4	–	Sell	-409,271	Closed	-$2.08M	–	2599
2016 Q3	$2.08M	Buy	409,271 +26,500	+7%	+$158K	0.01%	921
2016 Q2	$2.29M	Buy	382,771 +332,871	+667%	+$1.85M	0.01%	800
2016 Q1	$227K	Buy	+49,900	New	+$222K	﹤0.01%	1250

Other funds holding ENZ

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Arrowstreet Capital's ENZ Position: Q1 2018 in Review

Arrowstreet Capital sold out of Enzo Biochem, Inc. (ENZ) in Q1 2018, closing a stake of 287,375 shares — an estimated $2.34M sold.

Arrowstreet Capital first reported a position in ENZ in Q1 2016 and held it in 7 quarters. The position peaked at $4.08M in Q3 2017. 107 funds tracked by Wall St. Rank hold ENZ as of Q1 2018.

Arrowstreet Capital reported no remaining Enzo Biochem, Inc. position as of Q1 2018 after selling out during the quarter.
Arrowstreet Capital sold 287,375 Enzo Biochem, Inc. shares in Q1 2018, an estimated $2.34M.
Arrowstreet Capital first reported a position in Enzo Biochem, Inc. in Q1 2016 and held it in 7 quarters.
Arrowstreet Capital's Enzo Biochem, Inc. position peaked at $4.08M in Q3 2017.
107 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q1 2018.

Based on Arrowstreet Capital's 13F filing for Q1 2018, filed 14 May 2018.